Contact:
4008465777
-
About Us
News & Events
-
10-11
Global Expansion | Tonghua Dongbao's Insulin Glargine Injection Approved for Marketing in Myanmar
Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company") recently received marketing approval for its Insulin Glargine Injection from the regulatory authorities of Myanmar. This approval marks the Com...
-
07-02
Partnership | Tonghua Dongbao and Tofflon Enter into a Strategic Partnership to Drive Progress in Diabetes Treatment
Recently, Chairperson Li Jiahong and President Leng Chunsheng of Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") led a team to visit Tofflon Science and Technology Group ...
-
05-14
Global Expansion | Tonghua Dongbao's Mixed Isophane Protamine Human Insulin Injection Approved for Marketing in Nicaragua
Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company") recently received marketing approval for its Mixed Isophane Protamine Human Insulin Injection from the regulatory authorities of Nicaragua (ANR...
-
04-21
Breakthrough in GLP-1 Global Expansion | Tonghua Dongbao's Liraglutide Injection Receives GMP Certification from Colombia
Recently, the liraglutide injection, developed by Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or "the Company") and its partner, Kexing Biopharm Co., Ltd. ("Kexing Biopharm"), has rece...
-
04-03
Tonghua Dongbao: Dual-target inhibitor for gout (THDBH151 Tablets) completes phase IIa clinical trial summary report
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a Phase IIa pivota...
-
03-23
Global Expansion | Tonghua Dongbao's Mixed Isophane Protamine Human Insulin Injection (30R) Approved for Marketing in Uzbekistan
Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company") recently received marketing approval for its Mixed Isophane Protamine Human Insulin Injection (30R) from the regulatory authorities of Uzbekist...